BioSenic receives key European patent from EPO, for further therapeutic development in cancer, infectious and immune diseases

INSIDE INFORMATION Patent covers the therapeutic use of a new composite formulation of anti-inflammatory compounds with unique advantages BioSenic’s new formulation lowers the dosage of... | April 18, 2023

Related Keywords

Belgium ,France ,Mont Saint Guibert ,Waals Gewest ,Paris ,France General ,Louvain La Neuve ,Region Flamande ,French ,Belgian ,Annie Florence Loyer ,Michelle Boxall ,Seitosei Actifin ,Neil Hunter ,Bert Bouserie ,Ghislaine Gasparetto ,Biosenic Group ,European Patent Office ,Ib Communications ,International Media Enquiries ,Euronext Brussels ,Patent Office ,Chief Executive Officer ,Host Disease ,Arsenic Trioxide ,Systemic Sclerosis ,Mesenchymal Stromal Cells ,Graft Versus Host Disease ,Systemic Lupus ,Chief Executive ,Belgian Media ,Investor Enquiries ,French Media Enquiries ,French Investor Enquiries ,Biosenic Sa Stock Exchange ,News ,Information ,Press Release ,Inside ,Patent ,Overs ,The ,Herapeutic ,Tse ,F ,Few ,Composite ,Formulation ,Compounds ,Ith ,Unique ,Advantages ,Towers ,Osage Bios Be0974280126 ,